A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer. - Wikidata - awgldk - TriplyDB

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

http://www.wikidata.org/entity/Q33493803

about

A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

P2860

Q36081162-A9212DE4-50D2-42EF-98EC-6FD0AD2AA06A Q36354734-A23A7244-CAA0-4132-8A33-F32A8E29E462

P2860

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

http://www.wikidata.org/entity/Q33493803

description

1993 nî lūn-bûn

@nan

1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年学术文章

@wuu

1993年学术文章

@zh-cn

1993年学术文章

@zh-hans

1993年学术文章

@zh-my

1993年学术文章

@zh-sg

1993年學術文章

@yue

name

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@ast

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@en

type

label

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@ast

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@en

prefLabel

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@ast

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

@en

P1433

Q33493803-E781A683-F486-48C6-AB31-F60A808D36EA

P1476

Q33493803-2846FAE2-0628-434B-9667-DD9EF68F94EA

P2093

Q33493803-01236F68-863B-43DD-8A88-6369333A5EE5

Q33493803-023A28CF-297C-424D-BB40-2671C834DDB4

Q33493803-1342E05D-E615-45F9-9019-C8832AEADE44

Q33493803-2D6BBCD5-FC8D-4D88-95EE-438EB6DB00A8

Q33493803-54987A40-27E7-45F3-BEEF-E3187915EC72

Q33493803-63C23A37-42E3-4E10-BBA3-D344F700F34F

Q33493803-8CEB6CAC-B1EB-47DB-81C3-C3E972B78137

Q33493803-CEAABEEF-AE7A-428C-9628-C8EC7227DF49

P2860

Q33493803-1D6F5E1B-7823-4DFD-93F9-71D3343F0FF7

Q33493803-3A745A81-856C-4338-94E0-0C7C8D9C43D6

Q33493803-40E97B6B-9435-46A9-B957-5D264A18B5EC

Q33493803-485AC227-DF92-494B-9CD3-1DB326857BA9

Q33493803-889A9F7A-1112-469E-8953-984337B5219E

Q33493803-8939EF3B-36BC-4FFE-BE56-BC2F5B58A712

Q33493803-D69A924E-7B0F-46C9-987D-F166091D1703

Q33493803-E0EC5444-BC17-4BD2-8F29-5C323FC49DFE

Q33493803-E89B790C-3F92-46FB-B924-FEC43DE846C2

P2888

Q33493803-BF90643E-3498-48BB-B9BB-7A1EC7C2A7E8

P304

Q33493803-16FBD14A-109F-4061-AA75-18B82E0A77F7

P31

Q33493803-92E13058-7392-41C5-9EE4-E460A44A9F5B

P356

Q33493803-B79219EF-154D-4E05-B242-367CCD1A7E63

P407

Q33493803-53684AD9-888E-4314-82C3-B6363E0BEBD7

P433

Q33493803-2094670D-D18F-4B3E-89A6-FE64AE765104

P478

Q33493803-1D145D77-C1F0-412C-AFED-EBB1A434AE0F

P50

Q33493803-D0F8E261-BF00-4402-BA18-268B87DA1290

Q33493803-E9938328-F8A4-49B0-A01C-4C62219157D6

P577

Q33493803-F307EE43-D150-4A14-9A1C-416C90A079AF

P5875

Q33493803-1F6D9A44-9B44-4C4B-B63B-71089AC60F77

P6179

Q33493803-7244773D-EA8A-4A83-B800-28DDCDAF6B01

P698

Q33493803-6333C6DF-DCCA-4C09-9396-AC80F2204CF4

P932

Q33493803-44000A17-EC62-485C-BF93-E2C35EA2514A

P356

P1433

British Journal of Cancer

P1476

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer

@en

P2093

A Crawshaw

http://www.w3.org/2001/XMLSchema#string

D T Sleijfer

http://www.w3.org/2001/XMLSchema#string

H J Dobbs

http://www.w3.org/2001/XMLSchema#string

I Dennis

http://www.w3.org/2001/XMLSchema#string

J E Scott

http://www.w3.org/2001/XMLSchema#string

N H Mulder

http://www.w3.org/2001/XMLSchema#string

P H Willemse

http://www.w3.org/2001/XMLSchema#string

P Workman

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II study of piritrexim in patients with advanced squamous head and neck cancer.

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.

A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).

Initial clinical studies of piritrexim.

Oral piritrexim, an effective treatment for metastatic urothelial cancer

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.

Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.

Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.

Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.

P2888

P304

641-644

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1993.400

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Jourik A Gietema

Elisabeth de Vries

P577

1993-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14846357

http://www.w3.org/2001/XMLSchema#string

P6179

1000919287

http://www.w3.org/2001/XMLSchema#string

P698

8353055

http://www.w3.org/2001/XMLSchema#string

P932

1968400

http://www.w3.org/2001/XMLSchema#string